← Leaderboards
Rameen Beroukhim
Dana-Farber Cancer Inst
$9,639,646
Attributed
$19,737,436
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2007–25$2.5M$1.9M$1.3M$625K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,737,436 · 7
By mechanism
R01$14,841,408 · 4
U24$4,199,428 · 2
K08$696,600 · 1
Top collaborators
- Keith L Ligon24 shared
- Andrew David Cherniack10 shared
- Arnab Chakravarti5 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Rosalind A Segal$29,230,271
- Adam Joel Bass$9,339,125
- Andrew A Lane$4,246,865
- David Marc Weinstock$10,844,261
- Pratiti Bandopadhayay$2,988,759
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMutationTumorGenomeEventGenesGenomicsInnovationClinical TrialsSamplingNovel Therapeutic InterventionBaseRadiationCellsIn VivoHeterogeneityResolutionPreventResistanceRecurrenceStructureGeneticPathway InteractionsGlioma
Grant awards (39)
Evolution of gliomas during treatment and resistance$697,603
R01 · FY2025 · CA · contact PI
Synthetic lethalities to cell cycle disruption in glioma$673,491
R01 · FY2025 · CA · contact PI
Center for the Comprehensive Analysis of Cancer Somatic Copy-Number Alterations, Rearrangements, and Long-Read Sequencing Data$397,265
U24 · FY2025 · CA · contact PI
Evolution of gliomas during treatment and resistance$662,723
R01 · FY2024 · CA · contact PI
Synthetic lethalities to cell cycle disruption in glioma$639,818
R01 · FY2024 · CA · contact PI
Center for the Comprehensive Analysis of Cancer Somatic Copy-Number Alterations, Rearrangements, and Long-Read Sequencing Data$378,245
U24 · FY2024 · CA · contact PI
Evolution of gliomas during treatment and resistance$683,652
R01 · FY2023 · CA · contact PI
Synthetic lethalities to cell cycle disruption in glioma$660,022
R01 · FY2023 · CA · contact PI
Center for the Comprehensive Analysis of Cancer Somatic Copy-Number Alterations, Rearrangements, and Long-Read Sequencing Data$376,320
U24 · FY2023 · CA · contact PI
Evolution of gliomas during treatment and resistance$683,652
R01 · FY2022 · CA · contact PI
Synthetic lethalities to cell cycle disruption in glioma$668,921
R01 · FY2022 · CA · contact PI
Center for the Comprehensive Analysis of Cancer Somatic Copy-Number Alterations, Rearrangements, and Long-Read Sequencing Data$376,322
U24 · FY2022 · CA · contact PI
Evolution of gliomas during treatment and resistance$736,601
R01 · FY2021 · CA · contact PI
MYB family alterations in pediatric gliomas$554,504
R01 · FY2021 · CA
Characterizing TP53 and PPM1D mutations as resistance drivers to radiation therapy in Diffuse Intrinsic Pontine Gliomas$523,271
R01 · FY2021 · CA · contact PI
Center for the Comprehensive Analysis of Cancer Somatic Copy-Number Alterations, Rearrangements, and Long-Read Sequencing Data$384,002
U24 · FY2021 · CA · contact PI
MYB family alterations in pediatric gliomas$554,504
R01 · FY2020 · CA
Characterizing TP53 and PPM1D mutations as resistance drivers to radiation therapy in Diffuse Intrinsic Pontine Gliomas$517,874
R01 · FY2020 · CA · contact PI
Center for the comprehensive analysis of somatic copy-number alterations in cancer$445,290
U24 · FY2020 · CA · contact PI
Genetic evolution of glioblastomas during radiation and temozolomide therapy$656,695
R01 · FY2019 · CA · contact PI
MYB family alterations in pediatric gliomas$537,868
R01 · FY2019 · CA
Characterizing TP53 and PPM1D mutations as resistance drivers to radiation therapy in Diffuse Intrinsic Pontine Gliomas$497,259
R01 · FY2019 · CA · contact PI
Center for the comprehensive analysis of somatic copy-number alterations in cancer$440,258
U24 · FY2019 · CA · contact PI
Genetic evolution of glioblastomas during radiation and temozolomide therapy$682,620
R01 · FY2018 · CA · contact PI
MYB family alterations in pediatric gliomas$554,504
R01 · FY2018 · CA
Characterizing TP53 and PPM1D mutations as resistance drivers to radiation therapy in Diffuse Intrinsic Pontine Gliomas$507,552
R01 · FY2018 · CA · contact PI
Center for the comprehensive analysis of somatic copy-number alterations in cancer$462,082
U24 · FY2018 · CA · contact PI
Genetic evolution of glioblastomas during radiation and temozolomide therapy$689,449
R01 · FY2017 · CA · contact PI
MYB family alterations in pediatric gliomas$554,504
R01 · FY2017 · CA
Characterizing TP53 and PPM1D mutations as resistance drivers to radiation therapy in Diffuse Intrinsic Pontine Gliomas$502,615
R01 · FY2017 · CA · contact PI
Center for the comprehensive analysis of somatic copy-number alterations in cancer$467,292
U24 · FY2017 · CA · contact PI
Genetic evolution of glioblastomas during radiation and temozolomide therapy$697,496
R01 · FY2016 · CA · contact PI
Center for the comprehensive analysis of somatic copy-number alterations in cancer$472,352
U24 · FY2016 · CA · contact PI
Genetic evolution of glioblastomas during radiation and temozolomide therapy$704,210
R01 · FY2015 · CA · contact PI
High-resolution genome-wide mapping of structural mutations in prostate cancer$139,320
K08 · FY2011 · CA · contact PI
High-resolution genome-wide mapping of structural mutations in prostate cancer$139,320
K08 · FY2010 · CA · contact PI
High-resolution genome-wide mapping of structural mutations in prostate cancer$139,320
K08 · FY2009 · CA · contact PI
High-resolution genome-wide mapping of structural mutations in prostate cancer$139,320
K08 · FY2008 · CA · contact PI
High-resolution genome-wide mapping of structural mutations in prostate cancer$139,320
K08 · FY2007 · CA · contact PI